CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT
PROPOSED SHARE REPURCHASE MANDATE

This announcement is made by CF PharmTech, Inc. (the "**Company**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company announces that a resolution in relation to the proposed grant of a general mandate (the "**Share Repurchase Mandate**") to the Directors to repurchase the Company's issued H shares listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") has been considered and approved by the Board. The proposal will be submitted to the shareholders of the Company for consideration and approval at an extraordinary general meeting of the Company (the "**EGM**") to be held in due course.

An explanatory statement required by the Rules Governing the Listing of Securities on the Stock Exchange in connection with the proposed Share Repurchase Mandate will be set out in the circular of the EGM. The explanatory statement will contain all information reasonably necessary to enable the shareholders of the Company to make an informed decision on whether to vote for or against the resolution regarding the Share Repurchase Mandate at the EGM.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing
Chairperson, Executive Director and
Chief Executive Officer

Hong Kong, November 13, 2025

As at the date of this announcement, the Board comprises of Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.